ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cilofexor

Also written as “Cilofexor”, “CILO” and “Cilofexor Dose B”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary, led by 2 companies.

Drug pageCilofexor: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 25, 201913 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only121 open or runningphase 3since Mar 25, 2019Jan 11, 2016Dec 2028phase 2 · NCT07841977
Phenex Pharmaceuticals10 open or runningphase 2since Nov 19, 2013Nov 19, 2013none ahead

Also a collaborator on its studies: Novo Nordisk.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Phenex Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2013First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT01999101 · 12 enrolled · Austria
  2. Dec 9, 2017Named cilofexorINNProposed as its International Nonproprietary Name in WHO's List 118

TargetBeta

NR1H4 →read by rule
“Bile acid receptor FXR agonist”ChEMBL 37, by rule

Other programs on NR1H4

ProgramCompanyFurthest phaseStudies
LY4395089Eli Lillyphase 23

Studies

The one study Phenex Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01999101Non-alcoholic Fatty Liver Disease · Austria2CompletedJan 201512

How it is read

Names in the registry

  • “Cilofexor”, 7 entries
  • “CILO”, 2 entries
  • “Cilofexor Dose B”, 1 entry
  • “Cilofexor Dose A”, 1 entry
  • “Cilofexor (CILO)/Firsocostat (FIR)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.